Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493636 · ClinicalTrials.gov registry record · Phase 2
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00493636 is a Phase 2 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 160 participants.
The verdict
NCT00493636, a Phase 2 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The study is being conducted to compare progression-free survival in patients treated with sorafenib and gemcitabine/capecitabine versus patients treated with placebo and gemcitabine/capecitabine for locally advanced or metastatic breast cancer that has progressed during or following treatment with a bevacizumab-containing regimen.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Gemcitabine
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493636
The ClinicalTrials.gov registry entry for NCT00493636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00493636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493636 about?
NCT00493636 is a clinical study titled "1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy". The study is being conducted to compare progression-free survival in patients treated with sorafenib and gemcitabine/capecitabine versus patients treated with placebo and gemcitabine/capecitabine for locally advanced or metastatic breast cancer that has progressed during or following treatment with ...
What is the current status of trial NCT00493636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-06. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00493636?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Gemcitabine (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00493636?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.